Immix Biopharma

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of Tissue-Specific Therapeutics (TSTx)™ in oncology and inflammation. Our lead asset, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia. Drugs produced by our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific™ platform accumulate 3-5 times more at the intended treatment site compared to traditional drugs. Our TME Normalization™ technology enables our drug candidates to circulate in the blood, exit through tumor vasculature, and simultaneously attack all components of the tumor microenvironment or TME. We have discovered fundamental biological systems that link oncology and inflammation. Our pipeline includes preclinical tissue-specific therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.